Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 10/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475902 | 0.78 | CTSL (0.55) | NPC1RAB9ASMN1; SMN2L3MBTL1FAAH | |
| SCHEMBL4794507 | 0.78 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL10253093 | 0.75 | CASP8 (0.42) | L3MBTL1CTSLCTSBCTSS | |
| SCHEMBL3770630 | 0.74 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2L3MBTL1FAAH | |
| SCHEMBL25168799 | 0.74 | FAAH (0.49) | FAAH | |
| SCHEMBL30006556 | 0.72 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19902999 | 0.72 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18711879 | 0.72 | FAAH (0.59) | SMN1; SMN2L3MBTL1FAAH | |
| SCHEMBL1480507 | 0.71 | KDM4E (0.50) | NPC1RAB9ASMN1; SMN2L3MBTL1FAAH | |
| SCHEMBL655588 | 0.71 | PARP1 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | NPC1 482/4885RAB9A 1155/4885SMN1; SMN2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.